- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04081337
A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
A Randomized, Placebo-Controlled, Parallel-Arm Study to Investigate the Effect of Once-Weekly Tirzepatide on Energy Expenditure and Food Intake in Obese Subjects
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- Pennington Biomedical Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have body mass index of 30 to 45 kilograms per square meter (kg/m²), inclusive
- Have a stable body weight in the past 1 month prior to screening
- Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff
Exclusion Criteria:
- Have undergone gastric bypass or bariatric surgery
- Have a diagnosis of type 2 diabetes
- Have a history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs; of constituting a risk when taking the study drug; or of interfering with the interpretation of data
- Have received prescription drugs or over the counter drugs that promote weight loss in the past 6 months prior to screening
- Have any lifetime history of a suicide attempt
- Patient Health Questionnaire-9 (PHQ-9) score of 15 or more at screening
- Positive responses to selected items on the Columbia Suicide Severity Rating Scale (C-SSRS)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Participants received placebo once weekly (QW) by Subcutaneous (SC) injection.
|
Administered SC
|
Experimental: 15 Milligram (mg) Tirzepatide
Participants received 15 mg of tirzepatide QW by SC injection.
|
Administered SC
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR)
Time Frame: Baseline, Week 18
|
SMR was measured using whole-room indirect calorimetry (respiratory chamber).
Change from Baseline to Week 18 in SMR was evaluated.
Least square (LS) mean was determined by analysis of covariance (ANCOVA) model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.
|
Baseline, Week 18
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to Week 18 in Food Intake During Ad Libitum Meal
Time Frame: Baseline, Week 18
|
Ad libitum lunch and dinner were provided.
The sum of the caloric breakdown (carbohydrates, protein, and fats) was calculated from the respective nutritional information of the food items.
LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
|
Baseline, Week 18
|
Change From Baseline to Week 18 in 24-hour Energy Expenditure (EE)
Time Frame: Baseline, Week 18
|
24 hour energy expenditure was measured in a respiratory chamber.
LS mean was determined by ANCOVA model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.
|
Baseline, Week 18
|
Change From Baseline to Week 18 in 24 Hour Respiratory Quotient (RQ)
Time Frame: Baseline, Week 18
|
Respiratory quotient was calculated as the ratio of carbon dioxide production to oxygen consumption as measured in a metabolic chamber for 24 continuous hours.
Ratio of total carbon dioxide production (VCO2)/total oxygen consumption (VO2), from baseline to Week 18 was evaluated.
24-hour RQ = total VCO2 [Liter/24hour] / total VO2 [Liter/24hour].
LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
|
Baseline, Week 18
|
Change From Baseline to Week 18 in Sleep RQ
Time Frame: Baseline, Week 18
|
Sleep RQ is defined as the ratio of VCO2 to VO2 during sleep time points.
Change from baseline to Week 18 in sleep RQ is presented.
LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
|
Baseline, Week 18
|
Change From Baseline to Week 18 in Duration of Periods With RQ<0.80
Time Frame: Baseline, Week 18
|
RQ<0.80 is defined as the cut point for high lipid oxidation of RQ; lipid oxidation will be calculated and corrected for protein oxidation; the total number of minutes with RQ <0.80, termed "lipid oxidation duration," during each 23-hour measurement period will be recorded; protein oxidation will be determined from urine nitrogen that will be collected during 2 periods for each calorimeter day.
LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
|
Baseline, Week 18
|
Change From Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation
Time Frame: Baseline, Week 18
|
Change from Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation is presented.
Adjusted oxidation is calculated using the formula, Adjusted oxidation rate (g/day) = oxidation rate (g/day) / 24-hour Energy Expenditure) x 1000 (kcal/day). LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables. |
Baseline, Week 18
|
Change From Baseline to Week 18 in Body Weight (BW)
Time Frame: Baseline, Week 18
|
Change from baseline in BW through Week 18 in participants were presented.
LS mean was determined by mixed measures repeated model (MMRM) model with Baseline, Treatment, Time, Treatment*Time, Participant and Random Error as variables.
|
Baseline, Week 18
|
Change From Baseline to Week 18 in Body Fat-Free Mass
Time Frame: Baseline, Week 18
|
Change from baseline to Week 18 in body fat free mass is presented.
Body fat free mass was measured using dual energy X-ray absorptiometry (DXA) measurements.
LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
|
Baseline, Week 18
|
Change From Baseline to Week 18 in Body Fat Mass
Time Frame: Baseline, Week 18
|
Change from baseline to Week 18 in body fat mass is presented.
Body fat mass was measured using DXA measurements.
LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
|
Baseline, Week 18
|
Change From Baseline to Week 18 in Percentage of Body Fat Mass
Time Frame: Baseline, Week 18
|
The total body fat mass was measured in kilograms (kg) using DXA scanning.
Change from baseline to week 18 in percentage of body fat mass is reported.
LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
|
Baseline, Week 18
|
Change From Baseline to Week 18 in Lipid Metabolism Parameters
Time Frame: Baseline, Week 18
|
Change in Lipid Metabolism Parameters from baseline (week 0) to week 18 is evaluated.
Triglyceride, Very low density lipoprotein (VLDL), High density lipoprotein (HDL) cholesterol and free fatty acids values were reported.
Results below presents Area under the Curve (AUC) during standardized mixed-meal tolerance test (sMMTT).
LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
|
Baseline, Week 18
|
Change From Baseline to Week 18 in Fasting Insulin Resistance
Time Frame: Baseline, Week 18 during standardized mixed meal tolerance test
|
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) is a test that uses a simultaneous fasting blood glucose test and fasting insulin test to accurately estimate the degree of insulin resistance (IR) and β-cell function (the cells of the pancreas that produce insulin). HOMA-IR= [Fasting glucose (mmol/L) x (fasting insulin (picomoles per liter {pmol/L})/6)] / 22.5. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables. |
Baseline, Week 18 during standardized mixed meal tolerance test
|
Change From Baseline to Week 18 in Postprandial Insulin Sensitivity
Time Frame: Baseline, Week 18
|
Insulin sensitivity was measured from insulin and glucose levels obtained following standard meal challenge using a modification of the Matsuda index.
This was calculated based on data obtained from a 75 g oral glucose tolerance test, as follows: 10,000 divided by the square root of {(fasting glucose X fasting insulin) (total area under the glucose response curve (AUC) 0-4hr)) X total insulin AUC(0-4hr )}.
A Matsuda index of <2.5 indicates whole body insulin resistance.
A lower Matsuda Index indicates the worst disease state.
An increase in the Matsuda Index indicates an improvement in insulin sensitivity (best).
A positive change from Baseline indicates improvement and a negative change from Baseline indicates a worsening.
Stumvoll and oral glucose insulin sensitivity indexes were also used for measuring the insulin Sensitivity.
LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
|
Baseline, Week 18
|
Change From Baseline to Week 18 in Postmeal Total Glucose AUC During sMMTT
Time Frame: Baseline, Week 18
|
Total AUC from time zero to 4 hours after start of the meal [AUC0-4 hours]) during sMMTT was evaluated.
LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.
|
Baseline, Week 18
|
Change From Baseline to Week 18 in Hemoglobin A1c (HbA1c)
Time Frame: Baseline, Week 18
|
HbA1c is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.
LS mean was determined by ANCOVA model with Baseline, Treatment, Time, Treatment*Time, Participant and Random Error as variables.
|
Baseline, Week 18
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17092
- I8F-MC-GPGU (Other Identifier: Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
-
Consorcio Centro de Investigación Biomédica en...Maimónides Biomedical Research Institute of Córdoba; Instituto de Salud Carlos... and other collaboratorsActive, not recruiting
-
University of HoustonBaylor College of MedicineCompleted
Clinical Trials on Tirzepatide
-
Eli Lilly and CompanyActive, not recruitingGlucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Type2 Diabetes | Metabolic Disease | T2DM (Type 2 Diabetes Mellitus) | T2DUnited States, India, Australia, United Kingdom, Mexico, Brazil, Israel, France, Italy
-
Florida Academic Centers Research and Education...Not yet recruiting
-
Eli Lilly and CompanyCompletedType 2 Diabetes MellitusPuerto Rico, United States, Poland, Slovakia
-
Eli Lilly and CompanyRegeneron PharmaceuticalsNot yet recruitingObesityUnited States, Mexico
-
Nanjing First Hospital, Nanjing Medical UniversityRecruiting
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyRecruitingObesity | Type 2 DiabetesUnited States, Turkey, Mexico, Argentina, Israel, United Kingdom
-
Eli Lilly and CompanyCompletedObesity | Overweight | Type 2 DiabetesUnited States, Russian Federation, Taiwan, Argentina, Brazil, Japan, Puerto Rico, India